Page 107 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes

tacrine total placebo (n = 468) placebo; placebo/20 mg/d 20; 40; 60; 80 mg/d 71.3 71; 71.6 70.7; 71.9; 72.1; 70.8 52 49; 59 49; 50; 55; 47 97 91; 99 97; 97; 96; 99 18.5 18.2; 18.8 18.8, 18.4, 17.9, 19.2 0.6 0.5; 0.6 0.8, 0.5, 0.7, 0.6 27.5 28.1; 27 27, 28.4, 27.7, 26.6 Primary Outcome Measures: ADAS-Cog; CGIC Secondary Outcome Measures: ADAS-Noncog; ADAS total score; MMSE; caregiver-rated CGIC; Timing of assessments: Weeks 4, 6, 10 and 12 Health Outcome Measures: Significantly better PDS score only for TAC 40 mg/d compared to pla

PDS • • • • •

Final Report Update 1 Authors: Farlow et al. Year: 1992 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: (% white) Other germane population qualities: MMSE • HIS • ADAS-Cog • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs